Anemia Market
DelveInsight's "Anemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anemia, historical and forecasted epidemiology as well as the Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Anemia market report provides current treatment practices, emerging drugs, Anemia market share of the individual therapies, current and forecasted Anemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Anemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Anemia market.
Anemia Disease Understanding and Treatment Algorithm
The DelveInsight’s Anemia market report gives a thorough understanding of the Anemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Anaemia is a condition in which the number of red blood cells or the haemoglobin concentration is lower than normal. There is Haemoglobin (Hb) concentration below 13 g/dl in men over 15 years of age, below 12 g/dl in non-pregnant women over 15 years of age, and below 11 g/dl in pregnant women. If there are too few or abnormal red blood cells, or not enough haemoglobin, there will be a decreased capacity of the blood to carry oxygen to the body’s tissues.
The most common causes of anaemia include nutritional deficiencies, particularly iron deficiency, though deficiencies in folate, vitamins B12 and A are also important causes; haemoglobinopathies; and infectious diseases, such as malaria, tuberculosis, HIV and parasitic infections.
Anaemia can cause a range of symptoms. Iron-deficiency anemia often develops slowly. In the beginning, one may not have any symptoms, or they may be mild. As it gets worse, one or more of these symptoms fatigue (very common), weakness (very common), dizziness, headaches, low body temperature, pale or yellow "sallow" skin, rapid or irregular heartbeat, shortness of breath or chest pain, especially with physical activity, brittle nails, pica are observed.
Anemia Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Anemia.
Anemia Treatment
It covers the details of conventional and current medical therapies available in the Anemia market for the treatment of the condition. It also provides Anemia treatment algorithms and guidelines in the United States, Europe, and Japan.
Anemia Epidemiology
The Anemia epidemiology section provides insights about the historical and current Anemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Anemia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Anemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- According to World Health Organization (2011), it is estimated that roughly 43% of children, 38% of pregnant women, and 29% of non pregnant women and 29% of all women of reproductive age had anaemia.
- In a study by Sun and Wiever (2021), the US population was studied between 1999 and 2018, it was seen that dietary iron intake decreased by ∼6.6% and ∼9.5% for male and female adults, respectively. Increases of prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on age and sex.
- According to Office on Women’s Health (OWH), Iron-deficiency anemia affects more women than men and is more common during pregnancy.
Country Wise- Anemia Epidemiology
The epidemiology segment also provides the Anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Anemia Drug Chapters
The drug chapter segment of the Anemia report encloses the detailed analysis of Anemia marketed drugs and late-stage (Phase-III and Phase-II) Anemia pipeline drugs. It also helps to understand the Anemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Anemia Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Anemia treatment.
Anemia Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Anemia treatment.
Akebia Therapeutics: Vadadustat
Vadadustat (Akebia Therapeutics) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase III clinical development program for the treatment of anemia due to CKD. It is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan.
GlaxoSmithKline: Daprodustat /GSK1278863
Daprodustat /GSK1278863 (GlaxoSmithKline) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease (CKD). Daprodustat is currently not approved as a treatment for anaemia due to CKD or any other indication anywhere else in the world other than in Japan. Presently it is being evaluated in Phase III study for treatment of Anemia.
Nemysis: IHAT-02/ IDAX
IHAT-02/ IDAX (Nemysis), is novel oral iron formulation, the first natural ferritin mimic, where a tartrate salt is used to “dope” the ferrihydrite nanocore of ferritin, in an adipate buffer. IHAT (Iron Hydroxide Adipate Tartrate) is well absorbed and preserves the gut microbiome. Absorption studies and early nutritional trials in human have shown that IHAT is absorbed efficiently and corrects markers of iron deficiency, without the burden of gastrointestinal side effects. Currently the drug is being evaluated in a Phase II clinical trial for the treatment of Iron deficiency/ Anemia. The company was the first to file a nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority.
MegaPro Biomedical: MPB-1514/ IOP Injection
MPB-1514/ IOP Injection (MegaPro Biomedical), is the non- sugar iron injection being developed for the treatment of Iron deficiency anemia. It is highly secure as coated with PEG with good macrophage phagocytic results, high doses can be injected, which can effectively increase the number of red blood cells without frequent injections, providing greater convenience and compliance with doctor's orders for patients. The drug is currently being evaluated in a Phase II clinical study with iron deficient anemia patients.
Anemia Market Outlook
The Anemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Anemia market trends by analyzing the impact of current Anemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Anemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Anemia market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Anemia market in 7MM.
The United States: Anemia Market Outlook
This section provides the total Anemia market size and market size by therapies in the United States.
EU-5 Countries: Anemia Market Outlook
The total Anemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan: Anemia Market Outlook
The total Anemia market size and market size by therapies in Japan is also mentioned.
Anemia Drugs Uptake
This section focuses on the rate of uptake of the potential Anemia drugs recently launched in the Anemia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Anemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Anemia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Anemia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Anemia Pipeline Development Activities
The Anemia report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Anemia key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Anemia report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Anemia emerging therapies.
Reimbursement Scenario in Anemia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Anemia market trends, we take KOLs and SMEs ' opinion working in the Anemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Anemia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Anemia Market Report
- The report covers the descriptive overview of Anemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Anemia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Anemia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Anemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anemia market
Anemia Market Report Highlights
- In the coming years, the Anemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Anemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Anemia. The launch of emerging therapies will significantly impact the Anemia market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anemia
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Anemia Market Report Insights
- Anemia Patient Population
- Therapeutic Approaches
- Anemia Pipeline Analysis
- Anemia Market Size and Trends
- Anemia Market Opportunities
- Impact of upcoming Anemia Therapies
Anemia Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Anemia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Anemia Market
- Anemia Drugs Uptake
Anemia Market Report Assessment
- Current Anemia Treatment Practices
- Unmet Needs
- Anemia Pipeline Product Profiles
- Anemia Market Attractiveness
- Anemia Market Drivers
- Anemia Market Barriers
Key Questions
Anemia Market Insights:
- What was the Anemia drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Anemia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Anemia market size during the forecast period (2019-2032)?
- At what CAGR, the Anemia market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Anemia market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Anemia market growth till 2032, and what will be the resultant Anemia market Size in the year 2032?
- How would the unmet needs affect the Anemia market dynamics and subsequent analysis of the associated trends?
Anemia Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Anemia?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Anemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anemia?
- Out of all 7MM countries, which country would have the highest prevalent population of Anemia during the forecast period (2019-2032)?
- At what CAGR the Anemia patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Anemia treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Anemia in the USA, Europe, and Japan?
- What are the Anemia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Anemia?
- How many therapies are in-development by each company for Anemia treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Anemia treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Anemia therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the ongoing Anemia clinical studies and their status?
- What are the current challenges faced in Anemia drug development?
- What are the key designations that have been granted for the emerging therapies for Anemia?
- What are the global historical and forecasted Anemia market?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Anemia market
- To understand the future market competition in the Anemia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Anemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Anemia market
- To understand the future market competition in the Anemia market